Anti-CD19 CAR-T cell
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
Feb 25, 2025
Grant Date -
Jul 1, 2021
app pub date -
Nov 23, 2020
filing date -
Nov 23, 2020
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A chimeric antigen receptor is provided, including an extracellular segment, including a single-chain antibody region binding to an antigen human CD19 and a hinge region, a trans-membrane segment, including a trans-membrane domain of human CD8α linked to the hinge region of the extracellular segment and embedded in cell membrane of T lymphocyte, and an intracellular segment, including an intracellular domain of human CD8α, an intracellular domain of molecule 4-1BB and an intracellular domain of CD3 ζ chain. The single-chain antibody region includes a heavy-chain variable region and a light-chain variable region of the single-chain antibody, the hinge region includes an extracellular domain of human CD8 alpha (CD8α) of 55 amino acid residues and three alanine residues (AAA) located at the N-terminal of the extracellular domain of human CD8α, and the intracellular domain of human CD8α includes seven amino acid residues and linked to the trans-membrane domain of human CD8α.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully